Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bionxt Solutions Inc
(OP:
XPHYF
)
N/A
UNCHANGED
Last Price
Updated: 3:44 PM EST, Dec 21, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.2836
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
BioNxt Reports Update on Commercialization of Rotigotine Patch for Treatment of Parkinson's Disease
February 13, 2023
Via
ACCESSWIRE
InvestorNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: XPHYF) (FSE: 4XT) to Expand Portfolio with Precision Drug Delivery Technology
December 12, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Performance
More News
Read More
BioNxt Solutions Signs Term Sheet for Novel Precision Drug Coating Platform Technology
December 12, 2022
Via
ACCESSWIRE
InvestorNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: XPHYF) (FSE: 4XT) Holds Key Meetings, Advances Product at Frankfurt CPHI Conference
November 21, 2022
Via
Investor Brand Network
Topics
Supply Chain
Exposures
COVID-19
Supply Chain
BioNxt Solutions Reports on Frankfurt CPHI Conference
November 21, 2022
Via
ACCESSWIRE
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Changes Name to BioNxt Solutions Inc.
November 10, 2022
Via
Investor Brand Network
XPhyto Announces Name Change to BioNxt Solutions Inc.
November 10, 2022
Via
ACCESSWIRE
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Major Milestone on Path to Commercialization of Lead Product
October 18, 2022
Via
Investor Brand Network
XPhyto Reports Excellent Rotigotine In-Vitro/Ex-Vivo Results for Parkinson's Disease Treatment
October 18, 2022
Via
ACCESSWIRE
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Completion of Rotigotine TDS Patch Study
October 11, 2022
Via
Investor Brand Network
XPhyto Completes Rotigotine Transdermal Patch Optimization and Comparative Skin Absorption Study
October 11, 2022
Via
ACCESSWIRE
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks LOI to Identify Manufacturing, Strategic Business Opportunities
October 05, 2022
Via
Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Patent Application for Novel Psychedelic Compound Library
September 20, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Exploring Expanded Application of ODF Screening Tests
July 18, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Congratulates Dr. Raimar Loebenberg as Recipient of 2022 CSPS Award
June 27, 2022
Via
Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Expands European Team to Add Pharmaceutical Manufacturing Expert
June 08, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Reports Positive Results of Rotigotine Transdermal Patch Study
May 09, 2022
Via
Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Provides Update on Market, Product Development of Key Biosensor
April 12, 2022
Via
Investor Brand Network
XPhyto, Biosensors Market and Product Developments on Platform-Based Oral Dissolvable Biosensors for Oral Health and Infectious Disease
April 11, 2022
From
XPhyto Therapeutics Corp.
Via
AccessWire
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Update on Rotigotine Transdermal Patch Development
April 04, 2022
Via
Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Closes First Tranche of Private Placement
April 01, 2022
Via
Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Updates on Psychedelic Medicine Programs Progess, Novel Compounds Milestone
February 22, 2022
Via
Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Issues Update Regarding Its Three Primary Business Divisions
February 08, 2022
Via
Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces New Covid-ID Lab Sales Contracts
February 01, 2022
Via
Investor Brand Network
Exposures
COVID-19
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Provides Update on Integration of 3a-diagnostics GmbH
January 24, 2022
Via
Investor Brand Network
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.